Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Prostate Cancer
CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal
April 22nd, 2008
Accuray Incorporated (NASDAQ:ARAY), a global leader in the field of radiosurgery, announced that a study published in the April 1 issue of the International Journal of Radiation Oncology*Biology*Physics -- also known as the Red Journal -- demonstrates that the CyberKnife(R) Robotic Radiosurgery System can serve as a non-invasive means for delivering high dose rate (HDR) brachytherapy dosing. The study supports the CyberKnife System's clinical flexibility in treating prostate cancer and expands the non-invasive options available to clinicians and patients. HDR brachytherapy has been shown to be an extremely effective approach for treating prostate cancer, with...
Source: Cancer Weekly (2008-04-22)
|
